ICON_Jan2021_CellandGeneTherapy - 23

Cell and Gene Therapy Clinical Trials - The Promise and Complexity of Living Therapies

dusanpetkovic / iStockphoto

Specialty Lab
Services Vital to CGT
Clinical Trial Success

T

o date, the bulk of investment in cell and

safety and efficacy for new CGT development beyond

gene therapies (CGT) in oncology has

leukemia and lymphomas, including chimeric

focused on hematologic cancers. But as the

antigen receptor (CAR) T-cells and T cell receptor

immense promise of immunotherapies as an effec-

(TCR) therapies, requires significant expertise that

tive means of treating cancer continues to gain trac-

can help identify relevant biomarkers to inform

tion, more and more research programs in pharma

patient selection for clinical trials and ultimately the

and biotech companies are seeking ways to also treat

safety and efficacy of a candidate therapy.

solid tumors with these new medicines. Proving the

To achieve this in the CGT arena requires a broad
ClinicalOMICs.com

| 23

http://www.ClinicalOMICs.com

ICON_Jan2021_CellandGeneTherapy

Table of Contents for the Digital Edition of ICON_Jan2021_CellandGeneTherapy